Test Price
2,800 AED✅ Home Collection Available
LOXHD1 Gene – Autosomal Recessive Deafness Type 77 (DFNB77) – Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Executive Summary
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Processing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy (8 AM – 11 PM).
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed clinical specialists.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The LOXHD1 Gene NGS Test is a high-resolution genetic assay designed to identify pathogenic variants in the LOXHD1 gene responsible for autosomal recessive nonsyndromic hearing loss type 77 (DFNB77). This test leverages Next Generation Sequencing (NGS) technology to deliver comprehensive coverage of all coding exons and splice-site regions, enabling precise molecular diagnosis for early intervention and family planning.
| Feature | Our LOXHD1 NGS Test | Closest Alternative |
|---|---|---|
| Precision | NGS – Full gene sequencing (all exons, splice sites) with 99.9% sensitivity | Single-gene Sanger sequencing – limited to known hotspot regions; may miss deep intronic variants |
| Methodology | Next Generation Sequencing (NGS) on Illumina® platform with bioinformatic verification | Targeted mutation panel or microarray – cannot detect novel or rare private mutations |
| Turnaround Time | 3 to 4 Weeks with comprehensive clinical report | 4 to 6 Weeks for conventional Sanger-based multi-exon screening |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403 notes: "A positive LOXHD1 result provides crucial molecular confirmation of DFNB77, but it must be interpreted alongside audiological phenotyping and family history. Genetic variants of uncertain significance require cautious multidisciplinary correlation — never isolate the genetic report from the patient's clinical presentation. I encourage families to pursue post-test genetic counselling to fully understand carrier status implications and reproductive options."
1. Advisory – Medication Caution
Do not discontinue prescribed medication without consulting your doctor. This genetic test is diagnostic and does not substitute for ongoing audiological or medical management. Abrupt cessation of prescribed therapies — including corticosteroids, anticonvulsants, or diuretics — may precipitate serious adverse events unrelated to the genetic diagnosis.
2. Exclusion Criteria & Emergency Red Flags
- Exclusion: Patients with active chemotherapy within the last 14 days (may affect DNA integrity).
- Exclusion: Recent allogeneic bone marrow transplant (within 90 days) — donor DNA may confound results.
- Exclusion: Inability to provide informed consent or lack of a legal guardian for minors (per Federal Decree-Law No. 4 of 2016 on Medical Liability).
- ER Red Flag: If sudden worsening of hearing loss occurs with vertigo, tinnitus, or neurological deficits — seek emergency ENT evaluation immediately. Do not wait for genetic test results.
- ER Red Flag: Any signs of acute meningitis, head trauma with CSF leak, or sudden unilateral deafness require urgent hospital admission.
Patient FAQ & Clinical Guidance
1. What does the LOXHD1 Genetic Test detect, and who should consider it?
This NGS test detects pathogenic variants in the LOXHD1 gene causing autosomal recessive deafness type 77 (DFNB77), a hereditary sensorineural hearing loss condition. It is recommended for individuals with congenital or early-onset bilateral sensorineural hearing loss of unknown etiology, siblings of confirmed DFNB77 patients, and couples with a family history of consanguinity seeking preconception carrier screening. Early molecular diagnosis enables timely cochlear implantation candidacy assessment and informed reproductive planning.
2. How is the test performed and what sample types are accepted?
The test uses Next Generation Sequencing (NGS) on a whole blood sample, extracted DNA, or a single FTA card spot. Sample collection is performed by our DHA-licensed mobile nursing team at your home, and transported via certified cold-chain to preserve DNA integrity. VIP Mobile Phlebotomy is available daily from 8 AM to 11 PM.
3. How long do results take, and will I receive clinical interpretation support?
LOXHD1 NGS test results are delivered within 3 to 4 weeks in a comprehensive clinical report including variant classification per ACMG guidelines. Post-test telephonic clinical guidance is provided by our DHA-licensed genetic counselling team to explain the implications of your results — whether positive, negative, or a variant of uncertain significance (VUS). This service ensures you are not left interpreting complex genetic data alone and supports onward referral to ENT specialists or clinical geneticists as clinically indicated.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: This laboratory service adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) ensuring genomic data confidentiality, and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. The facility is DHA-licensed (License No. 1143) and ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139). All testing is performed under strict quality management systems compliant with international standards.
Clinical & Logistical Metadata
| Test Name | LOXHD1 Gene – Autosomal Recessive Deafness Type 77 (DFNB77) – Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Whole Blood, Extracted DNA, or FTA Card |
| Methodology Used | Next Generation Sequencing (NGS) on Illumina® Platform with Bioinformatic Verification |
| ICD-10-CM Code | H90.3 |
| LOINC Code | 82638-6 |
| DHA Facility License & Laboratory Address | DHA Facility License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians